Global X S&P Biotech ETF (ASX:CURE)
Australia · Delayed Price · Currency is AUD 45.17
-0.08 (-0.18%)
Aug 1, 2025, 3:47 PM AEST
-0.18% (1Y)
| Assets | 30.98M |
| Expense Ratio | 0.45% |
| PE Ratio | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | -13.55% |
| Volume | 1,561 |
| Open | 45.25 |
| Previous Close | 45.25 |
| Day's Range | 45.05 - 45.43 |
| 52-Week Low | 38.76 |
| 52-Week High | 54.72 |
| Beta | 0.92 |
| Holdings | 10 |
| Inception Date | Nov 8, 2018 |
About CURE
The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.
Asset Class Equity
Category Health Care
Stock Exchange Australian Securities Exchange
Ticker Symbol CURE
Provider Global X
Index Tracked S&P Biotechnology Select Industry
Performance
CURE had a total return of -13.55% in the past year, including dividends. Since the fund's inception, the average annual return has been 1.83%.
Top 10 Holdings
26.64% of assets| Name | Symbol | Weight |
|---|---|---|
| Moderna, Inc. | MRNA | 2.88% |
| Incyte Corporation | INCY | 2.75% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 2.71% |
| Halozyme Therapeutics, Inc. | HALO | 2.68% |
| Neurocrine Biosciences, Inc. | NBIX | 2.64% |
| United Therapeutics Corporation | UTHR | 2.63% |
| Regeneron Pharmaceuticals, Inc. | REGN | 2.63% |
| Insmed Incorporated | INSM | 2.62% |
| Gilead Sciences, Inc. | GILD | 2.56% |
| Amgen Inc. | AMGN | 2.54% |